keyword
MENU ▼
Read by QxMD icon Read
search

Vandetanib

keyword
https://www.readbyqxmd.com/read/27873490/egf-induced-ret-inhibitor-resistance-in-ccdc6-ret-lung-cancer-cells
#1
Hyun Chang, Ji Hea Sung, Sung Ung Moon, Han Soo Kim, Jin Won Kim, Jong Seok Lee
PURPOSE: Rearrangement of the proto-oncogene rearranged during transfection (RET) has been newly identified potential driver mutation in lung adenocarcinoma. Clinically available tyrosine kinase inhibitors (TKIs) target RET kinase activity, which suggests that patients with RET fusion genes may be treatable with a kinase inhibitor. Nevertheless, the mechanisms of resistance to these agents remain largely unknown. Thus, the present study aimed to determine whether epidermal growth factor (EGF) and hepatocyte growth factor (HGF) trigger RET inhibitor resistance in LC-2/ad cells with CCDC6-RET fusion genes...
January 2017: Yonsei Medical Journal
https://www.readbyqxmd.com/read/27855236/vandetanib-induces-a-marked-anti-tumor-effect-and-amelioration-of-ectopic-cushing-s-syndrome-in-a-medullary-thyroid-carcinoma-patient
#2
Hashem Bseiso, Naama Lev-Cohain, David J Gross, Simona Grozinsky-Glasberg
: A 55-year-old woman diagnosed with sporadic MTC underwent total thyroidectomy 20 years ago. After the first surgery, elevated calcitonin levels in parallel with local disease persistence were noted and therefore she underwent repeated neck dissections. During follow-up, multiple foci of metastatic disease were noted in the neck and mediastinal lymph nodes, lungs and bones; however, the disease had an indolent course for a number of years, in parallel with a calcitonin doubling time of more than two years and without significant symptoms...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27843809/effect-of-an-outreach-programme-on-vandetanib-safety-in-medullary-thyroid-cancer
#3
Lars Bastholt, Michael C Kreissl, Dagmar Führer, Ana L Maia, Laura D Locati, Léa Maciel, Yi Wu, Kevin N Heller, Alan Webster, Rossella Elisei
OBJECTIVES: Effective management of adverse events (AEs) following vandetanib treatment is important to maximize clinical benefits. We examined whether more frequent contact with vandetanib-treated patients reduced AEs of CTCAE grade 2 or higher. STUDY DESIGN: In this open-label, multicentre, phase III study, patients with locally advanced or metastatic medullary thyroid cancer were randomized to a patient outreach programme (outreach) or a standard AE monitoring schedule (vandetanib control) for 52 weeks...
September 2016: European Thyroid Journal
https://www.readbyqxmd.com/read/27825616/vandetanib-in-patients-with-previously-treated-ret-rearranged-advanced-non-small-cell-lung-cancer-luret-an-open-label-multicentre-phase-2-trial
#4
Kiyotaka Yoh, Takashi Seto, Miyako Satouchi, Makoto Nishio, Noboru Yamamoto, Haruyasu Murakami, Naoyuki Nogami, Shingo Matsumoto, Takashi Kohno, Koji Tsuta, Katsuya Tsuchihara, Genichiro Ishii, Shogo Nomura, Akihiro Sato, Atsushi Ohtsu, Yuichiro Ohe, Koichi Goto
BACKGROUND: RET rearrangements are rare oncogenic alterations in non-small-cell lung cancer (NSCLC). Vandetanib is a multitargeted tyrosine kinase inhibitor exhibiting RET kinase activity. We aimed to assess the efficacy and safety of vandetanib in patients with advanced RET-rearranged NSCLC. METHODS: In this open-label, multicentre, phase 2 trial (LURET), patients with advanced RET-rearranged NSCLC continuously received 300 mg of oral vandetanib daily. RET-positive patients were screened using a nationwide genomic screening network of about 200 participating institutions...
November 4, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27819766/safety-and-tolerability-of-vandetanib-in-japanese-patients-with-medullary-thyroid-cancer-a-phase-i-ii-open-label-study
#5
Keita Uchino, Masato Komoda, Junichi Tomomatsu, Takahiro Okamoto, Kiyomi Horiuchi, Akihito Tsuji, Yasuhiro Ito, Takuya Todo, Ki Rito, Shunji Takahashi
OBJECTIVE: In a Phase III trial, Western patients with medullary thyroid cancer (MTC) treated with the oral multikinase inhibitor vandetanib showed significantly improved progression-free survival (PFS) and objective response rate (ORR) compared with placebo. The biology of MTC and pharmacokinetics (PK) are similar for Japanese and Western patients; therefore, similar clinical benefit is anticipated in the Japanese population. This study evaluated the safety and tolerability of vandetanib in Japanese patients with unresectable locally advanced or metastatic MTC...
November 7, 2016: Endocrine Practice
https://www.readbyqxmd.com/read/27803005/vandetanib-in-pretreated-patients-with-advanced-non-small-cell-lung-cancer-harboring-ret-rearrangement-a-phase-ii-clinical-trial
#6
S-H Lee, J-K Lee, M-J Ahn, D-W Kim, J-M Sun, B Keam, T M Kim, D S Heo, J S Ahn, Y-L Choi, H-S Min, Y K Jeon, K Park
BACKGROUND: Chromosomal rearrangements involving RET, which are found in about 1% of non-small cell lung cancer (NSCLC), define a unique molecular subset. We performed this study to examine the efficacy and safety of vandetanib 300 mg daily in this patient population. PATIENTS AND METHODS: This study was a multi-center, open-label, phase II clinical trial. Patients were enrolled if they had metastatic or recurrent NSCLC with a RET rearrangement, which was confirmed by fluorescence in situ hybridization, had progressive disease against platinum-based doublet chemotherapy, and had a performance status of 0 to 2...
November 1, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27799362/animal-models-of-medullary-thyroid-cancer-state-of-the-art-and-view-to-the-future
#7
Giovanni Vitale, Germano Gaudenzi, Luisa Circelli, Marco Federico Manzoni, Andrea Bassi, Niccolò Fioritti, Antongiulio Faggiano, Annamaria Al Colao
Medullary thyroid carcinoma is a neuroendocrine tumour originating from parafollicular C cells accounting for 5-10% of thyroid cancers. Increased understanding of disease-specific molecular targets of therapy has led to the regulatory approval of two drugs (vandetanib and cabozantinib) for the treatment of medullary thyroid carcinoma. These drugs increase progression free survival, however, they are often poorly tolerated and most treatment responses are transient. Animal models are indispensable tools for investigating the pathogenesis, mechanisms for tumour invasion and metastasis, and new therapeutic approaches for cancer...
October 31, 2016: Endocrine-related Cancer
https://www.readbyqxmd.com/read/27798882/the-significant-role-of-cyclin-d1-in-the-synergistic-growth-inhibitory-effect-of-combined-therapy-of-vandetanib-with-5-fluorouracil-for-gastric-cancer
#8
Kazunori Yawata, Shinji Osada, Toshiyuki Tanahashi, Satoshi Matsui, Yoshiyuki Sasaki, Yoshihiro Tanaka, Naoki Okumura, Nobuhisa Matsuhashi, Takao Takahashi, Kazuya Yamaguchi, Kazuhiro Yoshida
BACKGROUND: 5-Fluorouracil (5-FU) has been a mainstay of chemotherapy for gastric cancer. Vandetanib is a tyrosine kinase inhibitor with inhibitory activity against vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR). We investigated the combination effect of vandetanib with 5-FU on gastric cancer cells. MATERIALS AND METHODS: Anticancer efficacy was assessed by 3-(4,5-dimethyl-2-tetrazolyl)-2,5-diphenyl-2H tetrazolium bromide assay of five gastric cancer cell lines, MKN1, MKN7, MKN45, MKN74, and TMK1...
October 2016: Anticancer Research
https://www.readbyqxmd.com/read/27792051/advances-and-controversies-in-the-management-of-medullary-thyroid-carcinoma
#9
Ana Luiza Maia, Simone Magagnin Wajner, Carla Vaz Ferreira Vargas
PURPOSE OF REVIEW: Medullary thyroid carcinoma (MTC) comprises approximately 4% of all malignant thyroid neoplasms. Although the majority of patients have a good prognosis, a subgroup of patients develops progressive disease and requires systemic therapy. Here, we focused on the current MTC therapeutic approaches and discussed the advantages and disadvantages of molecular targeted therapies. RECENT FINDINGS: Targeted molecular therapies that inhibit RET and other tyrosine kinase receptors involved in angiogenesis have been shown to improve progression-free survival in patients with advanced MTC...
January 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/27764191/validated-lc-ms-ms-method-for-the-quantification-of-ponatinib-in-plasma-application-to-metabolic-stability
#10
Adnan A Kadi, Hany W Darwish, Mohamed W Attwa, Sawsan M Amer
In the current work, a rapid, specific, sensitive and validated liquid chromatography tandem mass-spectrometric method was developed for the quantification of ponatinib (PNT) in human plasma and rat liver microsomes (RLMs) with its application to metabolic stability. Chromatographic separation of PNT and vandetanib (IS) were accomplished on Agilent eclipse plus C18 analytical column (50 mm × 2.1 mm, 1.8 μm particle size) maintained at 21±2°C. Flow rate was 0.25 mLmin-1 with run time of 4 min. Mobile phase consisted of solvent A (10 mM ammonium formate, pH adjusted to 4...
2016: PloS One
https://www.readbyqxmd.com/read/27742787/thyroid-cancer-risk-stratified-management-and-individualized-therapy
#11
Friedhelm Raue, Karin Frank-Raue
Thyroid cancer is the most common endocrine malignancy. Differentiated thyroid cancer (DTC) with the two subtypes, papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC), is the most frequent subtype of thyroid cancer; more rare subtypes are medullary thyroid cancer (MTC) and anaplastic thyroid cancer (ATC). The incidence of DTC has increased rapidly in recent years due to the more frequent use of imaging methods such as ultrasound of the neck and fine-needle aspiration (FNA) of thyroid nodules...
October 15, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27711083/radvan-a-randomised-phase-2-trial-of-wbrt-plus-vandetanib-for-melanoma-brain-metastases-results-and-lessons-learnt
#12
Avinash Gupta, Corran Roberts, Finn Tysoe, Matthew Goff, Jenny Nobes, James Lester, Ernie Marshall, Carie Corner, Virginia Wolstenholme, Charles Kelly, Adelyn Wise, Linda Collins, Sharon Love, Martha Woodward, Amanda Salisbury, Mark R Middleton
BACKGROUND: Brain metastases occur in up to 75% of patients with advanced melanoma. Most are treated with whole-brain radiotherapy (WBRT), with limited effectiveness. Vandetanib, an inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor and rearranged during transfection tyrosine kinases, is a potent radiosensitiser in xenograft models. We compared WBRT with WBRT plus vandetanib in the treatment of patients with melanoma brain metastases. METHODS: In this double-blind, multi-centre, phase 2 trial patients with melanoma brain metastases were randomised to receive WBRT (30 Gy in 10 fractions) plus 3 weeks of concurrent vandetanib 100 mg once daily or placebo...
November 8, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27683183/ret-aberrations-in-diverse-cancers-next-generation-sequencing-of-4-871-patients
#13
Shumei Kato, Vivek Subbiah, Erica Marchlik, Sheryl K Elkin, Jennifer L Carter, Razelle Kurzrock
PURPOSE: Aberrations in genetic sequences encoding the tyrosine kinase receptor RET lead to oncogenic signaling that is targetable with anti-RET multi-kinase inhibitors. Understanding the comprehensive genomic landscape of RET aberrations across multiple cancers may facilitate clinical trial development targeting RET. EXPERIMENTAL DESIGN: We interrogated the molecular portfolio of 4,871 patients with diverse malignancies for the presence of RET aberrations using Clinical Laboratory Improvement Amendments (CLIA) certified targeted next-generation sequencing (NGS) of 182 or 236 gene panels...
September 28, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27670779/targeting-neovasculature-with-multitargeted-antiangiogenesis-tyrosine-kinase-inhibitors-in-non-small-cell-lung-cancer
#14
Vasileios S Skouras, Charis Maragkos, Dimitra Grapsa, Konstantinos N Syrigos
Chemotherapy has reached a plateau in the efforts for survival improvement in non-small cell lung cancer (NSCLC). The growing knowledge of NSCLC molecular pathobiology has led to the development of new treatments that target specific tumor functions. Angiogenesis is a tumor function leading to the formation of new tumor vessels that are crucial for its survival. Although vascular endothelial growth factor (VEGF) plays a primary role in angiogenesis, the inhibition of the VEGF pathway with VEGF-receptor (VEGFR) tyrosine kinase inhibitors (TKIs) is associated with a modest survival benefit due to the development of resistance by the tumor that has been mainly attributed to the up-regulation of other stimulators of angiogenesis...
October 2016: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/27664392/systemic-treatment-and-management-approaches-for-medullary-thyroid-cancer
#15
Vinicius Ernani, Mukesh Kumar, Amy Y Chen, Taofeek K Owonikoko
Although rare, medullary thyroid cancer (MTC) exemplifies the value that ever-expanding knowledge of molecular pathways and mechanisms brings to managing challenging cancers. Although surgery can be curative for MTC in many patients, a substantial proportion of patients present with locoregional or distant metastatic disease. Once distant disease occurs, treatment options are limited, and conventional cancer treatments such as cytotoxic chemotherapy are of minimal benefit. Biomarkers such as calcitonin and carcinoembryonic antigen are important correlates of disease burden as well as predictors of disease progress, including recurrence and survival...
September 10, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27650489/the-safety-and-efficacy-of-vandetanib-in-the-treatment-of-progressive-medullary-thyroid-cancer
#16
Poupak Fallahi, Silvia Martina Ferrari, Enke Baldini, Marco Biricotti, Salvatore Ulisse, Gabriele Materazzi, Paolo Miccoli, Alessandro Antonelli
Traditional therapies for advanced or metastatic progressive medullary thyroid cancer (pMTC) are poor effective. Several TKIs have been tested in clinical trials in pMTC patients. Areas covered: This paper reviews efficacy and safety of vandetanib in the treatment of pMTC. Expert commentary: Vandetanib (trade name CAPRELSA® [Vandetanib]) has been shown to improve progression-free survival (30.5 vs 19.3 months in controls) in pMTC patients. Vandetanib is approved by FDA and EMA for metastatic MTC in adults; in adolescents and children with metastatic or locally advanced MTC, vandetanib seems to be effective...
November 2016: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/27633259/discovery-and-optimization-of-n-substituted-2-4-pyridinyl-thiazole-carboxamides-against-tumor-growth-through-regulating-angiogenesis-signaling-pathways
#17
Wenbo Zhou, Wenshu Tang, Zhenliang Sun, Yunqi Li, Yanmin Dong, Haixiang Pei, Yangrui Peng, Jinhua Wang, Ting Shao, Zhenran Jiang, Zhengfang Yi, Yihua Chen
Inhibition of angiogenesis is considered as one of the desirable pathways for the treatment of tumor growth and metastasis. Herein we demonstrated that a series of pyridinyl-thiazolyl carboxamide derivatives were designed, synthesized and examined against angiogenesis through a colony formation and migration assays of human umbilical vein endothelial cells (HUVECs) in vitro. A structure-activity relationship (SAR) study was carried out and optimization toward this series of compounds resulted in the discovery of N-(3-methoxyphenyl)-4-methyl-2-(2-propyl-4-pyridinyl)thiazole-5-carboxamide (3k)...
2016: Scientific Reports
https://www.readbyqxmd.com/read/27620278/multilayer-omic-data-in-medullary-thyroid-carcinoma-identifies-the-stat3-pathway-as-a-potential-therapeutic-target-in-retm918t-tumors
#18
Veronika Mancikova, Cristina Montero-Conde, Javier Perales-Paton, Agustin F Fernandez, Maria Santacana, Karolina Jodkowska, Lucía Inglada-Pérez, Esmeralda Castelblanco, Salud Borrego, Mario Encinas, Xavier Matias-Guiu, Mario F Fraga, Mercedes Robledo
PURPOSE: Medullary thyroid carcinoma (MTC) is a rare disease with few genetic drivers, and the etiology specific to each known susceptibility mutation remains unknown. Exploiting multilayer genomic data, we focused our interest on the role of aberrant DNA methylation in MTC development. EXPERIMENTAL DESIGN: We performed genome-wide DNA methylation profiling assessing >27,000 CpGs in the largest MTC series reported to date, comprising 48 molecularly characterized tumors...
September 12, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27618325/current-concepts-in-the-molecular-genetics-and-management-of-thyroid-cancer-an-update-for-radiologists
#19
Tatiana Kelil, Abhishek R Keraliya, Stephanie A Howard, Katherine M Krajewski, Marta Braschi-Amirfarzan, Jason L Hornick, Nikhil H Ramaiya, Sree Harsha Tirumani
Substantial improvement in the understanding of the oncogenic pathways in thyroid cancer has led to identification of specific molecular alterations, including mutations of BRAF and RET in papillary thyroid cancer, mutation of RAS and rearrangement of PPARG in follicular thyroid cancer, mutation of RET in medullary thyroid cancer, and mutations of TP53 and in the phosphatidylinositol 3'-kinase (PI3K)/AKT1 pathway in anaplastic thyroid cancer. Ultrasonography (US) and US-guided biopsy remain cornerstones in the initial workup of thyroid cancer...
September 2016: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/27586449/recent-updates-on-the-management-of-medullary-thyroid-carcinoma
#20
Bo Hyun Kim, In Joo Kim
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor derived from the thyroid C cells producing calcitonin. MTC accounts for 0.6% of all thyroid cancers and incidence of MTC increased steadily between 1997 and 2011 in Korea. It occurs either sporadically or in a hereditary form based on germline rearranged during transfection (RET) mutations. MTC can be cured only by complete resection of the thyroid tumor and any loco-regional metastases. The most appropriate treatment is still less clear in patients with residual or recurrent disease after initial surgery or those with distant metastases because most patients even with metastatic disease have indolent courses with slow progression for several years and MTC is not responsive to either radioactive iodine therapy or thyroid-stimulating hormone suppression...
September 2016: Endocrinology and Metabolism
keyword
keyword
20378
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"